Korea United Pharm held a seminar for medical professionals to launch its aspirin–clopidogrel combination, Clavixin Duo Capsule, in the Mongolian market.Last Thursday, Korea United Pharm invited over 50 Mongolian cardiologists to the Ramada Hotel in Ulaanbaatar for a launch seminar on Clavixin Duo C
Roche Korea outlined its expanding lymphoma portfolio during a media session at its headquarters in Seoul on Tuesday, presenting evidence for Polivy (polatuzumab vedotin) and Columvi (glofitamab) as global guidelines increasingly position both therapies at the center of diffuse large B cell lymphoma
Merck Healthcare Korea has designated 2025 as the starting point for its oncology business, saying it has completed a fully reimbursed cancer treatment portfolio in the Korean market and is now positioned to accelerate both patient access and pipeline expansion.The company emphasized what it calls t
SK plasma said it had signed a shareholders’ agreement with the Turkish Red Crescent (Kizilay) in Ankara, Türkiye, on Tuesday (local time). The agreement covers the construction of a PDMP plasma plasma-derived medicinal products) plant and the establishment of a joint venture named Proturk, aimed at
Treatment access for spinal muscular atrophy (SMA) in Korea remains constrained by structural barriers even as disease-modifying therapies become more widely available.SMA is a genetic neuromuscular disease in which a lack of survival motor neuron protein leads to progressive muscle weakness, respir
GC Biopharma announced on Monday that it received an “A” rating in the 2025 KCGS ESG Evaluation by the Korea Institute of Corporate Governance and Sustainability (KCGS), representing an upgrade from its previous rating.KCGS comprehensively evaluates the sustainable management levels of listed Korean
Yuyu Healthcare has commenced construction of its second factory in Hoengseong-gun, Gangwon Province, with an annual production capacity valued at 20 billion won ($13.5 million).This milestone follows the completion of Yuyu Healthcare's first factory in 2020, which has an annual production capacity
SK life science, the U.S. subsidiary of SK biopharmaceuticals, will present 10 poster studies on its anti-seizure medicine Xcopri (ingredient: cenobamate) at the 2025 Annual Meeting of the American Epilepsy Society (AES), to be held from Dec. 5 to 9 in Atlanta, Georgia, and will host a symposium to
“Recent hypertension treatment guidelines clearly prioritize dual-drug combination therapy—especially low-dose fixed-dose combinations—right from the beginning. Telminuvo is the most logical and effective choice, fully aligning with proven prescribing principles and offering an unmatched solution fo
Gilead Sciences is getting ready to move CAR-T up the ladder in Korea.Next year, the company plans to launch Yescarta as the first therapy in the country cleared for both second- and third-line diffuse large B-cell lymphoma (DLBCL), putting pressure on payers and hospitals to decide how early they a
Boryung announced its selection as an “XBRL (eXtensible Business Reporting Language) Financial Disclosure Excellence Corporation,” a recognition highlighting its leadership in transparent financial reporting.The Financial Supervisory Service (FSS) selects XBRL Financial Disclosure Excellence Corpora
GSK Korea's RSV vaccine, Arexvy, has expanded its indication to include high-risk individuals aged 50 to 59.High-risk groups for RSV infection include people with chronic respiratory disease, chronic cardiovascular disease, end-stage renal disease, and diabetes, as well as those living in nursing ho
Bayer Korea has earned the title of “2025 Great Place to Work in Korea” from the global management evaluation organization GPTW (Great Place to Work).GPTW is a global certification body that evaluates corporate culture in more than 180 countries. It assesses five core categories -- Trust, Respect, F
SK chemicals said Thursday it received an overall A+ rating in the 2025 ESG assessment conducted by the Korea Institute of Corporate Governance and Sustainability (KCGS), marking the fourth consecutive year it has earned the top-tier grade.Only two companies, including SK chemicals, have maintained
In a global phase 3 study of patients with HER2-positive advanced or metastatic gastroesophageal junction adenocarcinoma, combination therapy with zanidatamab (sold as Ziihera in the U.S.) significantly improved progression-free survival (PFS) and overall survival (OS) compared with the standard of
TriOar Biotechnology has signed a platform technology transfer and joint development option agreement with Celltrion for its TROCAD (TriOar’s Conditionally Activatable Domain) platform technology.The total contract value is $356 million (about 522 billion won) if all six target licenses are exercise
Yuyu Pharmaceutical has established a subsidiary in the United States to target the U.S. pet pharmaceuticals and health supplement market directly. This is its second move in the pet business, following its investment in a U.S. startup last April.Yuyu Pharmaceutical said Wednesday that it has invest
Novartis Korea said its factor B inhibitor Fabhalta (ingredient: iptacopan) has received expanded approval from the Ministry of Food and Drug Safety on Tuesday as a treatment option for adults aged 18 and older with complement 3 glomerulopathy (C3G).C3G is a rare chronic glomerulonephritis caused by
Ahngook Pharmaceutical said Tuesday that it signed a stock purchase agreement with Dimedi Korea last Friday.The acquisition supports Ahngook Pharm's goal to advance its “Business Diversification (H&B)”—a key part of its “2030 New Vision” strategy—and maintains its growth investment approach in line
A new non-statin oral lipid-lowering drug will likely enter the Korean clinical market.The Ministry of Food and Drug Safety is reviewing bempedoic acid for approval. If approved, it will expand treatment options for statin-intolerant and high-risk patients.Bempedoic acid reduces LDL-C and major card
